Last checked at 22 Apr 2014 07:01
Eden Research Plc
("Eden" or "Company")
First commercial launch of products using Eden technology
Eden Research plc (AIM: EDEN), the AIM listed natural micro-encapsulation company, announces that its licensee, TerpeneTech Ltd ("TerpeneTech"), has launched two pet odour neutralising products for companion animals in France. Both products utilise Eden's encapsulation technology and this marks the first ever commercial launch of products using Eden's intellectual property and expertise in encapsulation.
The two products, YP Odor Control Formula and YP Odor Control Seborrhea, were formulated and produced by TerpeneTech, Ltd and will initially be distributed in France by Laboratoires Agecom under its E Lotion brand, then moving on to other territories around the world. Both products are natural products that neutralize bad odours on dogs and cats.
TerpeneTech has a licence agreement with Eden for the use of Eden's patented encapsulation technology in consumer and agricultural related biocides. Under the agreement Eden will receive royalty income on the net sales of the product on an ongoing basis.
The two products take advantage of the natural defense mechanisms of plants, in the form of terpenes, and join them with Eden's encapsulation system enabling these active substances to be delivered in a controlled manner, over a period of time. Using Eden's technology the active ingredients in these products are released when they are needed from natural particles in contact with moisture, in these cases application can last for up to 18 days compared to the much shorter duration of effect from competitor products. They also have the advantage of soothing and helping to heal irritated skin, as well as improving the lustre and appearance of the animal's coat.
TerpeneTech is also developing other effective, proprietary natural Biocide consumer products for ant and cockroach baits, mosquito repellent, dust mites, and environmental sprays.
Clive Newitt, Managing Director of Eden comments: "The first commercial launch of products using our IP is a key milestone for the company and introduces the first stream of royalty revenues to the Company. The strategy of licensing our technology and receiving a royalty on product sales allows Eden to benefit from the development and commercialisation of these products by companies who have expertise in their particular market sector. We expect to see further revenues generated through royalties as more of our licensees bring their products to market in the near future."
Eden Research plc | www.edenresearch.com |
Clive Newitt, Managing Director | Tel: 01993 862 761 |
Alex Abrey, Chief Financial Officer | |
W H Ireland Limited | Tel: 0117 945 3471 |
John Wakefield | |
Walbrook PR Ltd | Tel: 020 7933 8780 or eden@walbrookpr.com |
Paul McManus | Mob: 07980 541 893 |
Notes:
Eden is an early stage revenue company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions to the global agrochemicals industry, the animal health industry, and consumer products.
Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with hydrophobic compounds both natural and synthetic. The technology uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.
Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.
With leading consultants in their respective fields, the Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.
The Company has a number of patents and has a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, identifying suitable industrial partners and entering into licence agreements.
Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.
For more information about Eden, please visit www.edenresearch.com